减肥
食欲
医学
肥胖
不利影响
脂肪组织
能源消耗
体重增加
药理学
重症监护医学
生物信息学
体重
内分泌学
生物
作者
Dagam Jeong,Ronny Priefer
出处
期刊:Life Sciences
[Elsevier]
日期:2022-10-01
卷期号:306: 120825-120825
被引量:2
标识
DOI:10.1016/j.lfs.2022.120825
摘要
As obesity prevalence increases, more and more drugs that assist with weight loss have been developed. Numerous weight loss drugs had been approved, but many have also been withdrawn based on their lack of efficacy as well as safety concerns. Initial approaches in developing weight loss drugs was by increasing physiological energy expenditure and suppressing the appetite. Subsequently, as more physiological mechanisms for weight gain has been unearthed, drugs targeting newly discovered receptors and/or enzymes have been introduced with improved safety profiles and fewer psychological adverse events. Additionally, drugs targeting hunger or satiety signaling have been actively studied, and have shown increased adoption by physicians. Studies have also evaluated drugs that target metabolic tissues—such as adipose tissue or muscle—to promote weight loss, however to-date nothing has carried on into clinical practice. Starting with a brief history of early obesity treatments, this review evaluates current weight loss pharmaceutical options based on their duration of therapy status.
科研通智能强力驱动
Strongly Powered by AbleSci AI